Actively Recruiting
EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell Transplantation
Led by Daihong Liu · Updated on 2026-02-27
18
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This exploratory clinical study focuses on the use of EBV-AST cell infusion for treating EBV-DNA viremia following allogeneic hematopoietic stem cell transplantation (Allo-HSCT). The study aims to determine the maximum tolerated dose (MTD) or optimal biological dose (OBD) of EBV-AST cells and assess their safety, tolerability, and preliminary efficacy in treating EBV-DNA viremia. The study will involve a 3+3 dose escalation design to evaluate three different dosages of EBV-AST cell infusion. The study is expected to provide important insights into the clinical application of cell-based therapies for EBV infections.
CONDITIONS
Official Title
EBV-AST Cell Therapy for EBV-Related Diseases After Stem Cell Transplantation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged between 18 and 75 years
- Have undergone allogeneic hematopoietic stem cell transplantation (Allo-HSCT)
- Have EBV-DNA viremia after transplant with viral load > 1000 copies/mL on two tests or > 10,000 copies/mL on one test
- Karnofsky Performance Score of 70 or higher
- Expected survival of at least 3 months
- Adequate organ function including kidney, liver, and blood counts
- Meet HLA-matching criteria between donor and recipient
You will not qualify if you...
- Active graft-versus-host disease (GVHD) grade 2 or higher or requiring > 0.5 mg/kg/day corticosteroids for GVHD
- History of CMV viremia or disease within the past week
- Diagnosed or suspected post-transplant lymphoproliferative disorder (PTLD) within 1 week before infusion
- Severe active infections other than EBV or CMV
- Serious allergic reactions or contraindications to the infusion
- Previous immune therapy-related adverse events of grade 3 or higher
- History of HIV, HCV, or HBV infection with active viral load
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Chinese PLA General Hospital
Beijing, China
Actively Recruiting
Research Team
D
Daihong Liu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here